GeneDx (NASDAQ: WGS) on Monday published research demonstrating that rapid genome sequencing delivers significant diagnostic benefits beyond intensive care units, potentially expanding its clinical utility in pediatric settings.
The study, published in Genetics in Medicine, evaluated over 1,000 pediatric inpatients across a 3.5-year period at Seattle Children’s, assessing rapid genome sequencing across neonatal, pediatric, and cardiac intensive care units as well as non-critical care inpatient wards. Findings showed an overall diagnostic yield of 35%, with non-ICU inpatient wards achieving the highest yield at 43%.
Notably, children evaluated for faltering growth exhibited a 63% diagnostic yield, with 37 distinct genetic diagnoses identified in 36 patients, including four cases of dual diagnoses. The research suggests that rapid genome sequencing can identify genetic conditions earlier in broader patient populations without requiring hospitals to expand genetics staffing significantly.
Beyond diagnostic performance, the study highlighted an additional benefit: hospital-wide implementation of rapid genome sequencing eliminated race-based disparities in access to testing. The findings challenge traditional assumptions about patient eligibility for rapid genome sequencing, particularly for children with faltering growth who have not historically been prioritized for such testing.
GeneDx, a provider of genomic testing services with a genomic dataset focused on rare diseases, markets ExomeDx and GenomeDx tests, both of which hold FDA Breakthrough Device designations. The company’s latest study underscores the potential for genomic testing to extend beyond critical care into broader pediatric care pathways.
